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Homing-associated molecules are of fundamental importance for proper functioning of our
immune system as they direct the cells to sites of inﬂammation to create an immune response. How-
ever, they are also responsible for harmful cell trafﬁcking, which takes place in acute and chronic
inﬂammations as well as in tumor progression and metastatic spread of cancer. Therefore, these
molecules are potential targets for developing drugs to prevent harmful inﬂammation and metas-
tases of cancer. In this review, we will discuss about the most recent advances in studies elucidating
the role of two homing-associated ecto-enzymes in physiological and pathological cell trafﬁcking
and their use as drug targets.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Homing-associated molecules are important in targeting
leukocytes and other cells into speciﬁc positions within the body.
Molecules, which guide leukocyte trafﬁcking, are of paramount
importance in the function of normal innate and acquired immu-
nity [1]. On the other hand, inappropriate migration of leukocytes
to various target organs is a key pathogenetic factor in a wide
spectrum of inﬂammatory diseases [2]. These include traditional
autoimmune diseases such as multiple sclerosis or rheumatoid
arthritis, as well as diseases like atherosclerosis, ischemia-reperfu-
sion injury, obesity and Alzheimer’s disease.
In addition to leukocytes, migratory nature is a hallmark of met-
astatic cancer cells. In fact, themalignant cells share with the leuko-
cytes the routes of migration within the body (blood and lymphatic
vasculature) and they also share many common molecular mecha-
nisms by which the cellular targeting is accomplished [3]. More-
over, the active roles of different pro- and anti-tumorigenicchemical Societies. Published by E
aining 3; EAE, experimental
lial venules; MDSC, myeloid
ve amine oxidase; TIL, tumor
ein-1
oratory, University of Turku,
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.leukocyte subclasses during the tumor progression have become
increasingly evident during the past few years [4]. In particular,
tumors seem to be able to evade the anti-tumor immunity by
inducing and attracting various immunosuppressive leukocyte
subtypes, such as regulatory T cells, type 2 macrophages and
myeloid-derived suppressor cells, into the growing tumor.
The leukocyte trafﬁcking molecules allow leukocytes to patrol
throughout the whole body [1,2]. Typically, the newly formed
mononuclear and polymorphonuclear leukocytes circulate freely
in the blood vasculature. At speciﬁc locations, such as in normal
high endothelial venules (HEV) in lymphoid organs, or in inﬂamed
venules in almost any organ they are able to leave the blood and
extravasate into the tissue. The extravasation cascade starts by
tethering and rolling of the leukocyte on the endothelial cells. If
followed by suitable activation stimuli, the leukocyte can then
ﬁrmly adhere to the endothelial cell, and ﬁnally transmigrate
through the inter-endothelial junctions, or through the endothelial
cell, into the tissue to exert its effector functions.
The distinct steps of the extravasation cascade are typically
mediated by different receptor–ligand pairs on the two opposing
cell types. Thus, selectins and their oligosaccharide-based ligands
presented on sialomucin-like proteins are key mediators of the
transient ﬁrst contacts, whereas chemokines and their receptors
are heavily involved at the activation step [5,6]. Thereafter, inte-
grins on the leukocytes and their ligands belonging to the immuno-
globulin super-family on the endothelium, together with certainlsevier B.V. All rights reserved.
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essential roles in the ﬁrm adhesion and transmigration [7–9].
In addition to these classical homing-associated molecules sev-
eral other proteins both on leukocytes and endothelial cells are
known to be critical in controlling leukocyte trafﬁcking. Among
these are vascular adhesion molecule-1 (VAP-1) and CD73, two dif-
ferent cell-surface expressed enzymes. Here we focus on the po-
tential role of these two molecules in controlling the movement
of leukocytes in inﬂammatory and malignant conditions. We will
give a brief overview on the earlier studies central to the concept
of ecto-enzymatic control of leukocyte trafﬁcking, but will focus
on the new advances that have been published since our latest
comprehensive review on this topic appeared in the beginning of
2008.
2. Discovery of the primary amine oxidase VAP-1
VAP-1 was originally reported as an endothelial adhesion mol-
ecule able to support lymphocyte adhesion to HEV in man [10]. It is
also inducible on the luminal surface of vessels with ﬂat-walled
endothelium under inﬂammatory conditions [11]. In addition to
endothelial cells, VAP-1 is abundantly present in adipose cells, in
which it is involved in glucose uptake, and in smooth muscle cells,
in which its functions remain poorly understood [12–15].
VAP-1 is a primary amine oxidase (E.C. 1.4.3.21; also known as
semicarbazide-sensitive amine oxidase (SSAO) or amine oxidase,
copper dependent 3 (AOC3) [16]. The enzymatic activity of VAP-1
converts soluble primary amines into the corresponding aldehydes
[17,18]. At the ﬁrst step of this two step reaction, the amine sub-
strate forms a transient Schiff-base with the enzyme, the enzyme
is reduced and then the corresponding aldehyde is released. In
the second half-reaction the enzyme is oxidized back to its original
state in a reaction, which also produces ammonium ions and
hydrogen peroxide. The catalytic activity of VAP-1 is critically
dependent on a tyrosine residue (at position 471 in human), which
is spontaneously self-processed into a topaquinone (6-hydroxyd-
opa) co-factor [19]. Despite the fact that the catalytic reaction dri-
ven by VAP-1 has been dissected in great detail, the identity of
soluble endogenous VAP-1 substrates still remain enigmatic. It is
known that both methylamine and aminoacetone, side products
of intermediary metabolism in man, can serve as good VAP-1 sub-
strates, but more abundant physiological substrates may well exist
[17].
The VAP-1 molecule consists of an extracellular part, which har-
bors the catalytic site, a transmembrane segment, and a short
intracellular N-terminal tail [20,21]. On the plasma membrane
VAP-1 normally forms a homodimer of two 90 kDa glycoproteins.
The extracellular part of each monomer consists of three domains
(D2-D4). VAP-1 has a relatively narrow substrate channel formed
by domains D4 and D3 and a key leusine (469 in human) guards
the entry of substrates. The large D4 domains, from each subunit,
form the dimer interface and each also contains a catalytic site,
buried at the base of a deep cleft.3. Anti-VAP-1 mAbs inhibit leukocyte migration in
inﬂammation
VAP-1 has been shown to regulate leukocyte-endothelial inter-
actions in a number of in vitro and in vivo models. Inhibition of
VAP-1 by function-blocking monoclonal antibodies inhibits lym-
phocyte, monocyte and granulocyte binding to HEV and inﬂamed
ﬂat walled vessels in many different tissues such as peripheral
lymph nodes, skin, heart, gut, synovium, kidney and liver in frozen
section assays [10,22–26]. The anti-VAP-1 mAbs also reduce roll-
ing, ﬁrm adhesion and transmigration of granulocytes and/orlymphocytes under conditions of laminar ﬂow on different types
of VAP-1 positive endothelial cells [27,28]. More recently, a unique
subpopulation of CD16+ monocytes has also been shown to rely
partially on VAP-1 in adhesion to and transmigration through he-
patic endothelial cells under shear [29]. In intravital videomicros-
copy studies, anti-VAP-1 mAbs reduce the number of rolling,
ﬁrmly adherent and transmigratory granulocytes [30,31]. In
in vivo animal models function-blocking anti-VAP-1 mAbs dimin-
ish inﬂammatory cell inﬁltration in many experimental models
including peritonitis, type 1 diabetes, hepatitis, skin inﬂammations
and allograft rejection [30,32–34].4. VAP-1 enzyme inhibitors attenuate inﬂammation
The function of VAP-1 cannot only be blocked by mAbs, but also
by speciﬁc inhibitors of its enzyme activity. Traditionally, small
carbonyl reactive substances such as hydroxylamine, semicarbaz-
ide or 2-bromoethylamine, have been employed as VAP-1 inhibi-
tors. Later on several new VAP-1 inhibitors belonging to
hydrazine derivatives (such as BTT-2052/SZE5302 and LJP1207),
haloalkylamines, arylalkylamines, propenyl- and propargylamines,
and oxazolidines with improved speciﬁcity and biocompatibility
have been developed [35,36].
With these inhibitors it has become evident that the enzymatic
activity of VAP-1 is important in the leukocyte extravasation, in
particular during the transmigration step. Thus, inhibition of exog-
enously or endogenously expressed VAP-1 by hydroxylamine or
semicarbazide signiﬁcantly reduces leukocyte transmigration
through an endothelial monolayer in in vitro ﬂow assays [28,37].
The inhibitors are also effective in alleviating inﬂammation in
in vivo models. This was initially demonstrated in air pouch
inﬂammation and adjuvant and anti-collagen antibody induced
arthritis models by BTT-2052 [27,38]. Later, enzymatic inhibition
of VAP-1 with different inhibitors has been successfully used to
ameliorate colitis, ischemia-reperfusion injury of lung, stroke,
experimental autoimmune encephalomyelitis (EAE), sepsis and
transplant rejection [39–42]. In the EAE model, VAP-1 inhibitors
showed notable efﬁcacy in preventing an already established
inﬂammatory response in the central nervous system even when
initiated later during the relapsing-remitting course of the disease
[42].
More recently, several publications have indicated that VAP-1
can inhibit leukocyte inﬁltration into the inﬂamed eye. In a rat
model of uveitis, the inﬂammation induced the expression of
VAP-1 in the vasculature of the retina [43]. An SSAO inhibitor alle-
viated accumulation of leukocytes in the different anatomical com-
partments of the eye. Also in a rat model of diabetic retinopathy,
inhibition of VAP-1 markedly reduced leukocyte transmigration
into the retina [44]. Moreover, in another rat eye model relevant
to age-related macular degeneration, SSAO inhibition signiﬁcantly
reduced the numbers of choroidal macrophages, and the amount of
neovascularization and the leakiness of the newly formed vessels
[45]. Very recently, VAP-1 was shown to be induced by IL-1 in a
corneal neovascularization model in mice. VAP-1 inhibitors inhib-
ited IL-1 induced type 2 macrophage inﬁltration and both angio-
genesis and lymphangiogenesis in that model [46]. Although
another member of the primary amine oxidase family, retina-spe-
ciﬁc amine oxidase AOC2, may contribute to the observed effects in
mice (and humans), rats lack this protein [47]. Moreover, VAP-1 is
expressed in the vasculature of the eye [48]. Nevertheless, all eye
models were done using a single 1,3-thiazole based SSAO inhibitor,
and it would be interesting to conﬁrm the observations using VAP-
1 deﬁcient mice. In any case the elegant eye models show that the
SSAO activity plays an important role in the generation of the
intraocular inﬂammatory response.
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notable anti-inﬂammatory effects in multiple in vivo models. Nev-
ertheless, the speciﬁcity of the inhibitors against other SSAO family
members, including retinal amine oxidase and diamine oxidase,
and possibly against some unrelated molecules, has not been
tested very thoroughly under in vivo conditions.
5. VAP-1 deﬁcient mice show altered inﬂammatory reactions
Generation of VAP-1 deﬁcientmice has conﬁrmed the enzymatic
and adhesive functions of this oxidase in vivo. Mice lacking VAP-1
are grossly normal but show almost complete absence of primary
amineoxidase activity in the tissue [31]. Thesemice showfaster roll-
ing (less efﬁcient leukocyte-endothelial cell contacts), reduced
number of ﬁrmly adherent cells, and a clear inhibition of leukocyte
transmigration into sites of inﬂammation. Moreover, inﬂammatory
reactions such as peritonitis and arthritis, and responses tomucosal
immunization are attenuated in the absence of VAP-1 [38,49].
VAP-1 also seems to contribute to leukocyte homeostasis in the
fat tissue. VAP-1 is induced in white adipose tissue in genetically
obese mouse strains [50]. Moreover, VAP-1 deﬁcient mice are
slightly more obese with larger white adipose tissues than their
wild-type controls [51]. Nevertheless, there were fewer T cells,
macrophages, NK cells and NKT cells in the fat tissue in the mice
lacking VAP-1. Thus, homing of different leukocyte subclasses into
fat, which is now known to be important for the induction of the
chronic low-state inﬂammation associated with obesity, is regu-
lated by VAP-1. Moreover, the VAP-1 deﬁcient mice provide a
new model of mild obesity, in which the numbers of fat cells and
inﬁltrating leukocytes are not directly associated to each other.6. VAP-1 modulates leukocyte migration into tumors
VAP-1 may support tumor progression. In early studies we
showed that anti-VAP-1 mAbs inhibit the adhesion of NK cells
and tumor inﬁltrating lymphocytes to VAP-1 positive neovessels
within the tumors [52]. More recently we have found that in
VAP-1 deﬁcient mice melanoma and lymphoma tumors grew more
slowly than in wild-type animals [53]. The tumors in VAP-1 /
host had defective angiogenesis, and impaired recruitment of mye-
loid-derived suppressor cells (MDSC). Notably, if the MDSC were
ablated from the mice, VAP-1 deﬁciency no longer protected the
animals. Moreover, genetic experiments with a transgenic mice
expressing an enzymatically inactive mutant of VAP-1 showed that
the effects on MDSC accumulation were dependent on the oxidase
activity of VAP-1.
The SSAO inhibitors also retard tumor progression. The SSAO
inhibitor treated mice show diminished numbers of Gr-1+
CD11b+ MDSC in the tumor as well as impaired neoangiogenesis
[54]. These experiments not only provide two independent lines
of evidence for the role of VAP-1 in leukocyte migration into the tu-
mors, but also suggest that targeting of VAP-1 might have potential
as an adjunctive treatment for the inhibition of tumor progression.
Currently we hypothesize that the VAP-1 expressing neoangio-
genic vessels in the tumor bind MSDC. As a consequence, the intra-
tumoral numbers of this particular pro-tumorigenic leukocyte
subtype are selectively increased, with a concomitant stimulation
of the neoangiogenesis and enhancement of the immune-
suppressing gene signature of the tumor microenvironment.
7. VAP-1 as a signaling molecule
Hydrogen peroxide has emerged to be a powerful signaling mol-
ecule at low concentrations [55]. VAP-1 derived hydrogen peroxide,
together with low dose vanadate, was initially shown to modulateglucose transport and GLUT4 recruitment by phosphorylating insu-
lin receptor substrate-1 and -3, and PI-3-kinase in rat fat cells [56].
Later on, VAP-1 derived H2O2 (without vanadate) has been found
to activate several key transcription factors including NF-kB and
p53 [57,58]. Hydrogenperoxide emerging from the catalytic activity
of VAP-1 increases the expression of classical adhesion molecules
such as E-selectin, P-selectin andMadCAM-1, and chemokines such
as CXCL8 in different in vitro and in vivo models [57,59,60]. Use of
mutant mice expressing an enzymatically inactive point mutation
in VAP-1 has veriﬁed in vivo that VAP-1 dependent up-regulation
of P-selectin and MadCAM-1 are dependent on the oxidase activity
of VAP-1 [59,60]. Thus, the enzyme-activity dependent adhesive
functions of VAP-1 may be at least partially mediated through the
H2O2-dependent signaling cascades, which alter the expression
and/or function of other homing-associated molecules.8. Novel counter-receptors of VAP-1 on the leukocyte
The leukocyte molecules(s) binding to VAP-1 have escaped
characterization for almost 20 years. Very recently, panning of
phage display libraries with recombinant VAP-1 has led to the
identiﬁcation of the ﬁrst cellular counter-receptors of VAP-1. These
experiments showed that VAP-1 binds to Siglec-9 and Siglec-10
proteins both in cell free protein-protein interaction assays and
in different cell based models [61] (and our unpublished results).
Siglecs belong to a family of lectin molecules, which bind to sia-
lic acids and mediate various adhesive and signaling events both
within the immune system and elsewhere in the body [62]. The
cellular distributions of Siglec-9 and -10 are very different: Sig-
lec-9 is expressed on all granulocytes, whereas Siglec-10 is present
mainly on B-cells. Based on molecular modeling it is plausible that
both Siglecs can present speciﬁc arginine residues into the enzy-
matic cavity of VAP-1. Although the side chain of arginine termi-
nates in a complex guanidinium structure rather than in a
normal primary amine, the arginine 293 of Siglec-10 has been
experimentally demonstrated to function as a substrate of VAP-1
[61]. Thus, these molecules can apparently serve as surface-bound
substrates of VAP-1. Currently it is not clear, whether the sialic acid
modiﬁcations of VAP-1 are necessary for the binding to Siglecs.
Siglec-VAP-1 interaction canbeutilized for imagingof inﬂamma-
tion in vivo (our unpublished results). Short synthetic Siglec-9 pep-
tides (containing the VAP-1 interacting core sequence) localize
selectively to sites of inﬂammation in vivo in VAP-1 expressing
transgenicmice, butnot inVAP-1deﬁcientmice. This ﬁnding is com-
patible with the fact that in normal non-inﬂamed vessels in the
periphery VAP-1 resides in cytoplasmic vesicles, from which it is
translocated onto the luminal surface only in inﬂammation [63].9. Dual mode of function of VAP-1: the current hypothesis
VAP-1 is believed to have both enzyme activity dependent and
enzyme activity independent adhesive functions [20]. The latter
ones are those blocked by anti-VAP-1 mAbs, which do not inhibit
theoxidase activity ofVAP-1.On theotherhand, a singlepointmuta-
tion at the critical Tyr 471 renders VAP-1 unable to support leuko-
cyte transmigration under ﬂow conditions. This mutant still
harbors the epitopes for anti-VAP-1mAbs, but its adhesion support-
ing properties cannot anymore be inhibited by anti-VAP-1 antibod-
ies. Moreover, in vitro ﬂow assays have shown that the anti-VAP-1
andSSAO inhibitor treatmentsdonotdisplay additive effects. There-
fore, we favor a model, in which a leukocyte ﬁrst makes a contact
with VAP-1 expressed on endothelial cells by using its counter-
receptor (Siglecs or other cell-surface expressed ligands) to interact
with the surface of VAP-1 (anti-VAP-1 antibody epitopes). Then, the
leukocyte canpresent a cell surface amine into the substrate channel
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but transient interaction of the counter-receptor (a substrate) with
the endothelial VAP-1 (an enzyme), modiﬁcation of the leukocyte
cell-surface substrate into an aldehyde and release of biologically
active hydrogen peroxide and ammonium.10. VAP-1 based clinical trials: a prognostic biomarker and a
potential drug target
A soluble form of VAP-1 (sVAP-1) is found in the blood of nor-
mal persons [64]. It is most likely formed by a proteinase-mediated
shedding of the endothelial and other surface expressed forms of
VAP-1 [65,66]. The concentration of sVAP-1 is increased in a lim-
ited set of inﬂammatory diseases. The most notable elevations
are seen in type 1 and type 2 diabetes and in certain liver diseases
such as alcholic and primary biliary chirrosis. [66–69]. In a striking
contrast to the majority of classical endothelial adhesion mole-
cules, sVAP-1 is not induced in many other inﬂammatory diseases
such as rheumatoid arthritis or inﬂammatory bowel diseases [66].
In type 2 diabetes, sVAP-1 even serves as an independent prognos-
tic marker for the diabetic complications and it predicts the risk for
cardiovascular and cancer mortality in these patients [26].
Increased sVAP-1 levels are also seen in cancer patients. Recent
studies indicate that patients with low sVAP-1 levels have signiﬁ-
cantly worse prognosis of colorectal cancer, and that sVAP-1 is an
independent marker of hepatic and lymph node metastasis in
these patients [70]. A similar correlation with low sVAP-1 and poor
prognosis was reported in gastric cancer [71].
The ample evidence from in vitro and preclinical in vivo models
demonstrates that VAP-1 contributes to the inﬂammatory reaction
in several different settings, and therefore it is a potential target for
anti-inﬂammatory therapeutics. It should be noted, however, that
there are certain important differences in the expression and func-
tion of VAP-1 between different species. One of the biggest differ-
ences is in liver. Sinusoidal endothelial cells in human liver express
high levels of VAP-1, whereas the corresponding vessels in mouse
express VAP-1 only very faintly or not at all under normal condi-
tions [22,72]. Moreover, mouse VAP-1 oxidates a wider repertoire
of substrates than human VAP-1 [72], which suggests the existence
of subtle differences in the active sites of the enzymes between the
two species. These differences should be taken into account when
designing inhibitors for human use and testing them in preclinical
mouse models.
To date only anti-VAP-1 antibodies have been administered to
patients. Initially, the original anti-VAP-1 mouse mAb 1B2 was
administered to contact dermatitis patients, and found to be safe,
but cleared from the circulation very rapidly [73]. This has led to
the development of chimeric and humanized, and lately, fully hu-
man anti-VAP-1 mAbs for clinical trials. The ﬁrst phase I/IIa studies
show that function-blocking fully human anti-VAP-1 mAbs are safe
and pharmacokinetically feasible reagents, when administered
into rheumatoid arthritis or psoriasis patients. Importantly, they
also suggested preliminary therapeutic efﬁcacy (http://www.
biotie.com/en/recearch_and_development/inﬂammation/vap1_
antibody). Analyses of the efﬁcacy of anti-VAP-1 blockade in clin-
ical settings await for further studies. The development of multiple
novel small molecular VAP-1 enzyme inhibitors by different phar-
maceutical companies also indicates that blocking of this modality
of VAP-1 function seems to be therapeutically attractive.11. CD73 – regulator of adenosine production
CD73 is an ectoenzyme (ecto-50-nucleotidase, EC 3.1.3.5)
mainly expressed on endothelial and epithelial cells and on a sub-
set of lymphocytes, especially on regulatory T cells. It is a part ofextracellular ATP metabolism and catalyzes conversion of AMP to
adenosine. Adenosine is highly anti-inﬂammatory, since it in-
creases endothelial barrier function and has suppressive effects
on leukocytes. It exerts its effects via adenosine receptors A1,
A2A, A2B and A3. Depending on the triggering pathway and aden-
osine concentration the effects can be either activating or inhibit-
ing. In inﬂammatory conditions, increased adenosine levels lead
to diminished production of activating cytokines and decreased
expression of certain adhesion molecules such as E-selectin and
ICAM-1 on endothelium and beta 2 integrins on leukocytes [74–
77].12. Distinct roles of CD73 on lymphatic and vascular
endothelium
CD73 participates in leukocyte extravasation from the blood
into the inﬂamed tissues. Experimental evidence suggests that
when a leukocyte binds to endothelial CD73, its enzymatic activity
becomes inhibited leading to decreased adenosine production. The
remaining adenosine is rapidly degraded by adenosine deaminase.
Thus, this process facilitates leukocyte transmigration through the
vascular endothelium [78].
Besides vascular endothelium, the lymphatic endothelium is
also CD73 positive. Interestingly, CD73 seems to be so far the only
molecule discriminating the afferent and efferent arms of the
lymphatics. It is expressed on afferent but not on efferent lymph-
atics. In general, lymphocyte recirculation routes between blood
and lymphoid tissues are well known. Also the molecular mecha-
nisms mediating lymphocyte entry from the blood via the postcap-
illary venules into the tissues have been thoroughly analyzed
[1,2,5–9]. In contrast, much less is known about the trafﬁcking
mechanisms of leukocytes within lymphatics. All leukocytes can
enter the lymph node via the afferent lymphatics, but only lym-
phocytes can leave the node via the efferent ones. Thus, the traf-
ﬁcking mechanisms via the afferent lymphatics into the draining
lymph nodes and those responsible for the continuation of the
lymphocyte journey via the efferent lymphatics are presumably
different. Therefore, we recently analyzed the role of CD73 in
lymphatics and, against our expectations, found that lymphatic
CD73 did not contribute to the migration. Instead, lymphocyte
CD73 was important in mediating lymphocyte migration via the
afferent lymphatics. Thus, we can currently conclude that CD73
on blood vessel endothelium and on lymphatic endothelium have
distinct adhesive roles [79].13. CD73 both on cancer cells and tumor inﬁltrating leukocytes
contribute to the cancer behavior
CD73 is also expressed on malignancies such as leukemia and
certain cancers of epithelial cell origin [80,81]. It is thought to pro-
vide survival advantage to the cancer cells by providing a salvage
pathway in situations, where antimetabolites are used as cancer
treatments to block the de novo synthesis of purines [82]. In fact,
expression and activity of CD73 on cancer cells is associated with
poor prognosis and may promote metastasis [83,84].
Experimental cancer models have provided excellent tools to
dissect the mechanisms behind this phenomenon more thor-
oughly. Gene expression proﬁling of tumor xenografts has shown
CD73 to associate to lymph node metastases of breast cancer
[85] and expression arrays have revealed that CD73 can protect
leukemic cells from TRAIL-induced apoptosis [86]. Involvement
of cancer cell CD73 in metastasis is well in line with the role
of lymphocyte CD73 in normal migration of lymphocytes via
afferent lymphatics into the draining lymph nodes [79]. More-
over, CD73-derived adenosine acting via A2A receptor has been
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metastasis of tumor cells as well [87]. An additional mode of ac-
tion of tumor CD73 is down-regulation of anti-tumor immunity,
since blockade of its adenosinergic effects improves adoptive T
cell therapy [88]. Although many of the CD73 effects are conse-
quences of its adenosine production, also more direct interac-
tions have been reported. The protection from TRAIL-induced
apoptosis does not involve enzymatic activity of CD73. Instead,
it is thought to be mediated by direct binding of CD73 to the
death receptor 5 [86].
Furthermore, CD73 of the host origin contributes to tumor
behavior. Tumor inﬁltrating lymphocyte population contains vari-
able number of regulatory T cells. They are considered to be harm-
ful as they dampen the anti-tumor immune response. CD73 on
regulatory T cells and adenosine A2A receptor on activated T cells
form immunosuppressive loops [89] and this may be envisaged to
take place between the lymphocyte pools in cancer. The existing
literature clearly demonstrates that CD73 exerts its functions in
several ways during cancer development and acts both on cancer
cells and non-malignant host cells. Overall, the mechanisms seem
to work for the beneﬁt of the cancer cells by helping them to es-
cape the immuno-surveillance.
Knockout mice have been valuable in searching for the role of
the host CD73 in cancer development [90,91]. In colon cancer, lym-
phoma, mammary tumor and melanoma models lack of host CD73
leads to retarded tumor growth. This is due to decreased numbers
of suppressive type 2 macrophages within the tumors and in-
creased activity of CD8 positive T cells. The studies have further re-
vealed that pro-tumorigenic effects of regulatory T cells are
dependent on their CD73 expression and endothelial CD73 may
be critical in promoting lung metastases [91].14. Lack of CD73 leads to different consequences in mouse and
man
The central role of CD73 at sites of inﬂammation and hypoxic
conditions can be realized in knockout mice lacking CD73 [92–
94]. These animals show enhanced leukocyte adhesion to vascular
endothelium in an ischemia-reperfusion model [95] and increased
vascular leakiness and leukocyte migration to inﬂammatory sites
in acute lung injury [96]. All this is in perfect agreement with the
known role of adenosine in inﬂammation. However, the ﬁndings
regarding brain inﬂammation in EAE model have been surprising,
because mice lacking CD73 are protected from the disease [97].
The results obtained in EAE suggest that both lymphocyte and
endothelial CD73 is needed for proper entrance of lymphocytes
into the brain in EAE. This suggests an organ speciﬁc role for
CD73 in inﬂammation and less signiﬁcant contribution of CD73-
derived adenosine to endothelial leakiness in murine blood-
brain-barrier than in vasculature elsewhere in the body. In this
context it is important to note, that expression of CD73 in the mur-
ine brain is different from that in human brain [97,98]. Only occa-
sional CD73 positive vessels can be found in murine brain, whereas
CD73 is expressed abundantly in the vasculature of human brain.
Regarding CD73 another difference can be detected on afferent
lymphatics, most of which are CD73 positive in humans. In con-
trast, only a minority of these lymphatics expresses CD73 in mouse
[76].
Recently mutations in human CD73 gene have been identiﬁed
leading to decreased CD73 concentrations and enzymatic activity.
These patients suffer from symptomatic calciﬁcations in lower-
extremity arteries and in hand and foot joint capsules. Therefore,
it is believed that CD73 is involved in the pathways preventing ec-
topic calciﬁcation [99]. This has not been observed in CD73 deﬁ-
cient mice.15. Clinical implications of CD73
When evaluating the potential of a particular target for drug
development it should be remembered that the data obtained with
mouse disease models may not be directly transferable to humans,
because the expression and/or function of the murine homolog
may differ from that of humans. Thus, caution is also warranted
when evaluating the results obtained from CD73 studies per-
formed in mouse.
Due to its anti-inﬂammatory effects adenosine is a potent sub-
stance to alleviate inﬂammation. However, due to its extremely
short half-life its use is not very feasible in clinics. Theoretically,
mediators up-regulating endogenous CD73 could serve as alterna-
tives providing a more constant increase in CD73-derived adeno-
sine. Such factors are interferon-beta and alpha. Both these
interferons up-regulate human CD73 on vasculature without hav-
ing any effects on CD73 on lymphocytes and cancer cells [81,98].
Similarly, interferon-beta up-regulates murine endothelial CD73
and gives protection in acute lung injury in mice [96]. A clinical
phase II study with interferon-beta is ongoing in patients suffering
from severe lung inﬂammation (http://www.faronpharmaceuti-
cals.com/).
One large patient group getting interferon-beta medication is
patients suffering from multiple sclerosis (MS). CD73 in these pa-
tients’ sera and endothelial CD73 increase subsequent to inter-
feron-beta therapy and this correlates with clinical improvement
of the patients [98]. Thus, part of the efﬁcacy of interferon-beta
therapy in MS disease may be mediated by CD73. It can be envi-
sioned that interferon-beta up-regulates CD73 on brain vascula-
ture leading to increased adenosine production. Adenosine
improves endothelial barrier function that results in diminished
inﬁltration of the inﬂammatory cells into the brain.
Statins have also been shown to up-regulate CD73 and adeno-
sine production. They may be beneﬁcial as a short-term therapy,
when transient CD73 increase is needed for example in ischemia-
reperfusion injury or as a pre-conditioning treatment [100,101].
Their long-term effects, however, may be questionable as in vitro
studies have demonstrated that statins increase CD73 expression
and activity by preventing its endocytosis without increasing its
synthesis [102]. Clinical trials with statins meant to target CD73
independently of their cholesterol lowering effects are ongoing or
recently completed (http://clinicaltrials.gov/).
In oncology, CD73 seems to be harmful as it enhances tumor
growth and metastasis both in various pre-clinical models and in
human tumors [84,87,88,90]. In this disease group, inhibition of
CD73 would hypothetically be beneﬁcial. In preclinical models
anti-CD73 antibody therapy, small molecular inhibitors of CD73
as well as targeting of adenosine receptor A2A have shown their
potential [87,88,90]. Whether they will also show efﬁcacy in the
clinical settings remains to be seen in future. Potentially also other
adenosine receptors can be targeted to prevent tumor growth. A3
adenosine receptor agonists are able to suppress survival and pro-
liferation of colon carcinoma cells in murine tumor models [103].
They can also decrease proliferation and metastasis of rat prostate
cancer cells [104]. Moreover, an A3 receptor agonist induced
apoptosis and inhibited tumor growth of hepatocellular carcinoma
in rats [105]. Whether A3 receptor agonists are also beneﬁcial for
patients will be evaluated in a currently ongoing clinical trial
targeting hepatocellular carcinoma (http://www.canﬁte.com/
CF102.htm).16. Conclusions
Aberrant leukocyte trafﬁcking to sites of inﬂammation is often
harmful leading to tissue damage and migrating malignant cells
Fig. 1. The role of CD73 and VAP-1 in cancer and inﬂammation. Expression of CD73 and VAP-1 on different cell populations is indicated (symbols or negative) and their key
functional consequences are summarized. Also the enzymatic reactions catalyzed by these enzymes are shown (top). Big yellow arrows indicate the overall contribution of
these molecules in cancer and inﬂammation. Immunosuppressive leukocytes include regulatory T cells, type 2 macrophages and MDSC. See the text for the details.
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the harmful trafﬁc are theoretically excellent targets to cure
inﬂammations and prevent cancer spread. VAP-1 and CD73 are
both ectoenzymes, which act via direct interactions with their
counter-receptors and more importantly, exert their effects via
the end-products of their enzymatic activity. The end-products
are potent mediators that have several effects modulating the cel-
lular microenvironments. In the case of VAP-1 the end-products
are pro-inﬂammatory, whereas adenosine produced by CD73 is
highly anti-inﬂammatory. Thus it would be beneﬁcial to suppress
VAP-1 and activate CD73 to alleviate inﬂammatory reactions. How-
ever, in cancer both CD73 and VAP-1 have serious unwanted prop-
erties leading to accelerated cancer growth, metastasis formation
and suppression of the anti-tumor immune response. Therefore,
in this diverse entity inhibition of both VAP-1 and CD73 appears
desirable. In the context of CD73 it is important to note that up-
regulation of CD73 by interferon-beta therapy is unlikely to cause
a threat of cancer progression, since in cancer the contribution of
lymphocyte and cancer cell CD73 rather than endothelial CD73 ap-
pears to be critical [81]. A schematic presentation of the role of
CD73 and VAP-1 in cancer and inﬂammations is shown in Fig. 1.In comparison to other trafﬁcking-associated molecules, ecto-
enzymes provide pharmaceutical industry with unique targets, be-
cause their enzymatic activity offers additional approaches for
modulation with small molecular drugs. Based on their properties
and results obtained so far from pre-clinical and clinical studies
VAP-1 and CD73 are potential candidates to treat inﬂammation
and cancer. The current and future clinical trials will show their
true value in clinical medicine.References
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